# NCT03924895 (NCT03924895)

> Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03924895
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urinary Bladder Cancer, Muscle-invasive
- Interventions: Pembrolizumab; Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Enfortumab Vedotin
- Enrollment: 595
- Primary outcome: Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone

## Commentary we found

- X threads: 164
- YouTube: 102
- Podcasts: 79
- X videos: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03924895

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03924895", "email": "<work email>"}; the inbox owner confirms by the emailed link.